Differential expression patterns of capping protein, protein phosphatase 1, and casein kinase 1 may serve as diagnostic markers for malignant melanoma

Melanoma Research

Volumn 21, Issue 4, 2011, Pages 335-343

  Sun, Daxin ^a,b   Zhou, Mian ^b   Kowolik, Claudia M ^b   Trisal, Vijay ^b   Huang, Qin ^b   Kernstine, Kemp H ^b   Lian, Fangru ^c   Shen, Binghui ^b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

capping protein; casein kinase 1; melanoma; protein phosphatase 1

Indexed keywords

CAPPING PROTEIN Z LINE ALPHA1; CASEIN KINASE IALPHA; PHOSPHOPROTEIN PHOSPHATASE 1; PROTEIN; PROTEIN PHOSPHATASE 1 CATALYTIC SUBUNIT BETA ISOFORM; UNCLASSIFIED DRUG;

ARTICLE; DIAGNOSTIC VALUE; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOCYTE; MELANOMA; MELANOMA CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; UPREGULATION; WESTERN BLOTTING;

BLOTTING, WESTERN; CAPZ ACTIN CAPPING PROTEIN; CASEIN KINASE I; CELL LINE, TUMOR; CHI-SQUARE DISTRIBUTION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOCYTES; MELANOMA; PREDICTIVE VALUE OF TESTS; PROTEIN PHOSPHATASE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 79960701069     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e328346b715     Document Type: Article

References (35)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-249.
2. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature 2007; 445:851-857.
3. Lawson DH. Update on the systemic treatment of malignant melanoma. Semin Oncol 2004; 31:33-37. (Pubitemid 38609791)
4. Wong SL, Coit DG. Role of surgery in patients with stage IV melanoma. Curr Opin Oncol 2004; 16:155-160. (Pubitemid 38402530)
5. Keller G, Schally AV, Nagy A, Baker B, Halmos G, Engel JB. Effective therapy of experimental human malignant melanomas with a targeted cytotoxic somatostatin analogue without induction of multi-drug resistance proteins. Int J Oncol 2006; 28:1507-1513.
6. Sarnaik AA, Weber JS. Recent advances using anti-CTLA-4 for the treatment of melanoma. Cancer J 2009; 15:169-173.
7. Ohsie SJ, Sarantopoulos GP, Cochran AJ, Binder SW. Immunohistochemical characteristics of melanoma. J Cutan Pathol 2008; 35:433-444. (Pubitemid 351519417)
8. Trefzer U, Rietz N, Chen Y, Audring H, Herberth G, Siegel P, et al. SM5-1: a new monoclonal antibody which is highly sensitive and specific for melanocytic lesions. Arch Dermatol Res 2000; 292:583-589. (Pubitemid 32112965)
9. McKee PH. Clues to the diagnosis of atypical melanocytic lesions. Histopathology 2010; 56:100-111.
10. Caldwell JE, Heiss SG, Mermall V, Cooper JA. Effects of Cap Z, an actin capping protein of muscle, on the polymerization of actin. Biochemistry 1989; 28:8506-8514. (Pubitemid 19269044)
11. D'Angelo A, Garzia L, Andre A, Carotenuto P, Aglio V, Guardiola O, et al. Prune c AMP phosphodiesterase binds nm23-H1 and promotes cancer metastasis. Cancer Cell 2004; 5:137-149. (Pubitemid 38283800)
12. Liao H, Li Y, Brautigan DL, Gundersen GG. Protein phosphatase 1 is targeted to microtubules by the microtubule-associated protein Tau. J Biol Chem 1998; 273:21901-21908. (Pubitemid 28405368)
13. Diatchenko L, Lau YF, Campbell AP, Chenchik A, Moqadam F, Huang B, et al. Suppression subtractive hybridization: a method for generating differentially regulated or tissue-specific c DNA probes and libraries. Proc Natl Acad Sci USA 1996; 93:6025-6030. (Pubitemid 26190796)
14. Geng M, Wallrapp C, Muller-Pillasch F, Frohme M, Hoheisel JD, Gress TM. Isolation of differentially expressed genes by combining representational difference analysis (RDA) and c DNA library arrays. Bio Techniques 1998; 25:434-438. (Pubitemid 28447486)
15. Gress TM, Hoheisel JD, Lennon GG, Zehetner G, Lehrach H. Hybridization fingerprinting of high-density c DNA-library arrays with c DNA pools derived from whole tissues. Mamm Genome 1992; 3:609-619.
16. Gress TM, Muller-Pillasch F, Geng M, Zimmerhackl F, Zehetner G, Friess H, et al. A pancreatic cancer-specific expression profile. Oncogene 1996; 13:1819-1830. (Pubitemid 26377516)
17. Stennett LS, Riker AI, Kroll TM, Cha Mberlin J, Miki T, Nickoloff BJ, et al. Expression of gp100 and CDK2 in melanoma cells is not co-regulated by a shared promoter region. Pigment Cell Res 2004; 17:525-532. (Pubitemid 39279072)
18. Van Dinten LC, Pul N, Van Nieuwpoort AF, Out CJ, Jager MJ, Van den Elsen PJ. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens. Invest Ophthalmol Vis Sci 2005; 46: 24-30. (Pubitemid 40041175)
19. Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci USA 2005; 102:6092-6097. (Pubitemid 40594260)
20. Troxel DB. Pitfalls in the diagnosis of malignant melanoma: findings of a risk management panel study. Am J Surg Pathol 2003; 27:1278-1283. (Pubitemid 37040591)
21. Aman A, Piotrowski T. Cell migration during morphogenesis. Dev Biol 2010; 341:20-33.
22. Wear MA, Yamashita A, Kim K, Maeda Y, Cooper JA. How capping protein binds the barbed end of the actin filament. Curr Biol 2003; 13:1531-1537. (Pubitemid 37078410)
23. Yamashita A, Maeda K, Maeda Y. Crystal structure of Cap Z: structural basis for actin filament barbed end capping. Embo J 2003; 22:1529-1538. (Pubitemid 36417402)
24. Oliver CJ, Terry-Lorenzo RT, Elliott E, Bloomer WA, Li S, Brautigan DL, et al. Targeting protein phosphatase 1 (PP1) to the actin cytoskeleton: the neurabin I/PP1 complex regulates cell morphology. Mol Cell Biol 2002; 22:4690-4701. (Pubitemid 34620405)
25. Tan I, Ng CH, Lim L, Leung T. Phosphorylation of a novel myosin binding subunit of protein phosphatase 1 reveals a conserved mechanism in the regulation of actin cytoskeleton. J Biol Chem 2001; 276: 21209-21216.
26. Niitsu N, Nakamine H, Okamoto M, Akamatsu H, Honma Y, Higashihara M, et al. Expression of nm23-H1 is associated with poor prognosis in peripheral T-cell lymphoma. Br J Haematol 2003; 123:621-630. (Pubitemid 37468058)
27. Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC. PTK787/ZK222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, decreases glioma growth and vascularization. Neurosurgery 2004; 55:426-432. discussion 432.
28. Kelly K, Averbuch S. Gefitinib: phase II and III results in advanced non-small cell lung cancer. Semin Oncol 2004; 31:93-99. (Pubitemid 38241026)
29. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99:3530-3539. (Pubitemid 34534519)
30. Stone RM, De Angelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 2005; 105:54-60. (Pubitemid 40053063)
31. Berger W, Elbling L, Minai-Pour M, Vetterlein M, Pirker R, Kokoschka EM, et al. Intrinsic MDR-1 gene and P-glycoprotein expression in human melanoma cell lines. Int J Cancer 1994; 59:717-723. (Pubitemid 24358598)
32. Depeille P, Cuq P, Mary S, Passagne I, Evrard A, Cupissol D, et al. Glutathione S-transferase M1 and multidrug resistance protein 1 act in synergy to protect melanoma cells from vincristine effects. Mol Pharmacol 2004; 65:897-905. (Pubitemid 38420495)
33. Kruczynski A, Hill BT. Vinflunine, the latest Vinca alkaloid in clinical development: a review of its preclinical anticancer properties. Crit Rev Oncol Hematol 2001; 40:159-173. (Pubitemid 33001600)
34. Sinnberg T, Menzel M, Kaesler S, Biedermann T, Sauer B, Nahnsen S, et al. Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. Cancer Res 2010; 70:6999-7009.
35. Biechele TL, Camp ND, Fass DM, Kulikauskas RM, Robin NC, White BD, et al. Chemical-genetic screen identifies riluzole as an enhancer of Wnt/b-catenin signaling in melanoma. Chem Biol 2010; 17:1177-1182.